Navigation Links
Study shows benefit of new maintenance therapy for multiple myeloma
Date:5/11/2012

Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. A medical procedure called autologous hematopoietic stem cell transplantation, commonly known as a stem cell transplant, is frequently an important treatment option for many patients.

Unfortunately, multiple myeloma continues to progress even after a transplant. A study published today in the New England Journal of Medicine offers promising news about a new long-term therapy, lenalidomide, that can be used after transplantation to slow down the progression of the disease.

Thomas Shea, MD, Director of the Bone Marrow and Stem Cell Transplant Program and Associate Director for Outreach Programs at UNC Lineberger and Don Gabriel, MD, Professor of Medicine in the division of hematology/oncology, were both co-authors on the clinical trial, which measured the effect of maintenance lenalidomide therapy on disease-free progression after transplant.

The phase 3 study demonstrated that maintenance therapy with lenalidomide, an oral drug that can be taken for many months or even years, is associated with significant improvement in outcomes for patients with newly diagnosed myeloma who have undergone a transplant. The probability of surviving free of disease progression (the primary end point) for three years was 59 percent in the lenalidomide group, as compared with 35 percent in the placebo group.

"The results of this trial will change our treatment of multiple myeloma patients," said Dr. Shea.

"While lenalidomide has some risks, including an increase in people developing second cancers, it generally appears to be well-tolerated when given long-term and was associated with a delay in time to progression of the myeloma as well as an improvement in overall survival" he added.

Shea noted that another study in France showed similar improvement in delaying progression of the myeloma following transplant, but did not improve how long patients lived after their transplant compared to those receiving a placebo. Additional studies need to be conducted and longer follow-up of the current studies will need to be undertaken to confirm whether there is a real survival benefit of lenalidomide therapy for these patients.


'/>"/>
Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. First, Second Kidney Transplants Have Similar Success: Study
2. Oxygen Therapy Slows Type 1 Diabetes in Mice, Study Says
3. Email Vacations Boost Job Productivity, Lower Stress: Study
4. Stem Cell Study Shows Promising Results Against Heart Failure
5. Fitness in Middle Age Lowers Medical Costs Later: Study
6. Smell Tests Dont Predict Alzheimers, Study Finds
7. Only Half of Meds Taken by Kids Have Adequate Safety Info: Study
8. OHSU study: Misdiagnosis of MS is costing health system millions per year
9. Evolution May Explain Runners High, Study Says
10. Infection Causes 1 in 6 Cancers Worldwide: Study
11. Wheelchair Breakdowns on the Rise, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... , ... With the cold weather here, many people will have to clear snow with snow ... amounts of snow, but they can be dangerous when used incorrectly. That’s why Amica ... the proper use of snow blowers:, , When removing wet snow ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Cosmetic Town, ... plastic surgery procedures in order to make it easier for their readers to get ... the body they impact as well as the techniques used on those particular areas. ...
(Date:1/19/2017)... ... January 19, 2017 , ... Bio-Optronics Inc. is proud ... CTMS workflow designed to seamlessly integrate and streamline the way researchers prepare and ... page, maximizing usability and improving efficiency significantly for users – a first in ...
(Date:1/19/2017)... ... 19, 2017 , ... Ultimate Medical Academy (UMA) is preparing ... about making a difference in the lives of the next generation of healthcare ... healthcare educational institution, has more than 30,000 alumni and employs more than 2,000 ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the third year running, ... and the surrounding area, is inaugurating a charity event to help raise ... as Lou Gehrig's disease or motor neurone disease, is a deadly neurological disorder ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... January 19, 2017 New ... to Address Motor Symptoms and Motor Complications in ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) C ... European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
(Date:1/19/2017)... , Jan. 18, 2017 The Global ... understanding and access to partnering deals and agreements entered ... Trends in partnering deals - Top deals by value ... of development, technology type The report provides understanding ... into by the world,s leading healthcare companies. The ...
(Date:1/19/2017)... 18, 2017 South Korea ... GlobalData,s new report, "South Korea Insulin Delivery Market Outlook ... Korea Insulin Delivery market. The report provides value, in ... prices (USD) within market segments - Insulin Pens, Insulin ... The report also provides company shares and distribution shares ...
Breaking Medicine Technology: